期刊文献+

吡哆胺对体外晚期糖基化及其终产物形成的抑制作用 被引量:3

Inhibitory effects of pyridoxamine on advanced glycation and advanced glycation end products formation in vitro
下载PDF
导出
摘要 目的体外观察吡哆胺对晚期糖基化和晚期糖基化终产物(AGEs)形成的抑制作用。方法应用牛血清白蛋白-葡萄糖试验和N-乙酰-甘氨酰-赖氨酸甲基酯-核糖两种体外试验,观察吡哆胺对糖基化反应及AGEs形成的抑制效果。结果牛血清白蛋白-葡萄糖试验显示,吡哆胺对糖基化反应具有明显抑制效果。在50 mmol/L和200 mmol/L葡萄糖浓度下,当吡哆胺浓度为50 mmol/L时,相对抑制率均在50%以上。200 mmol/L吡哆胺对糖基化的抑制作用最强,其相对抑制率分别达到92.12%和86.73%。N-乙酰-甘氨酰-赖氨酸甲基酯-核糖试验证明,吡哆胺能明显抑制晚期糖基化产物AGEs的形成。随着吡哆胺剂量的增大,吡哆胺对AGEs形成的抑制作用明显增强。结论吡哆胺对体外晚期糖基化反应和AGEs形成有明显抑制作用。 Objective To investgate inhibitory effect of pyridoxamine on advavced glycation and formation of advanced glycation end products(AGEs) in vitro. Methods BSA-glucose assay and N-acetyl-glycyl-lysine methyl ester-ribose assay were applied to determine the inhibitory effects of pyridoxamine on glyeation reaction and AGEs formation in vitro. Results In BSA-glucose assay, pyridoxamine exhibited an inhibitory effect on glyeation reaction. In 50 mmol/L and 200 mmol/L of glucose, 50 mmol/L of pyridoxamine showed that the relative inhibitory rates were more than 50%, 200 mmol/L of pyridoxamine had the most inhibitory effect on glycation reaction, the relative inhibitory rates were 92.15% and 86.730/0, respectively. Pyridoxamine exhibited an inhibitory activity on AGEs formation as detected by N-acetyl-glycyl-lysine methyl ester-ribose assay. The inhibitory effect of pyridoxamine on AGEs formarion was icreased with increasing concentrations applied pyridoxamine. Conclusion pyridoxamine displayed significantly inhibitory effect on advanced glycation reaction and AGEs fomnation in vitro.
出处 《中国实验诊断学》 2005年第5期783-785,共3页 Chinese Journal of Laboratory Diagnosis
基金 吉林省科学技术厅资助项目(20010545)
关键词 吡哆胺 晚期糖基化 晚期糖基化终产物 pyridoxamine advanced glycation advanced glycation end products
  • 相关文献

参考文献8

  • 1Singh R, Barden A, Mori T, et al. Advanced glycation end-products:a review[J]. Diabetologia, 2001,44( 1 ) : 129.
  • 2李才,侯芳玉,刘忠英.糖基化终产物形成抑制剂研究的进展[J].中国新药杂志,2001,10(2):85-88. 被引量:18
  • 3Bahbar S,Yemeni.KK, Scott S, et al. Noval inhibitors of advanced glycation endproducts(Part Ⅱ )[J]. Mole Cell Biol Res Commun, 2000,3(6) :360.
  • 4Khalifah RG, Baynes JW, Hudson BG. Amadorins:novel post-Amadori inhibitors d advanced glycation reactions[J]. Biochem Biophys Res Commun, 1999,257(2) :251.
  • 5Jain SK, Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and( Na^+ + K^+ )-ATPase activity reduction in high glucose-treated human erythrocytes[J]. Free Radical Biol Med, 2001,300(3):232.
  • 6Voziyan PA, Motz TO, Baynes JW, et al. A post-Amadori inhibitor pyridoxamine also inhibitschemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation [ J ]. J Biol Chem, 2002,277(5) :3397.
  • 7Motz TO, Alderson NL, Thorpe SR, et al. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications[J]. Arch Biochem Biophys, 2003,419(1):41.
  • 8Alderson NL, Chachich ME, Frizzell N, et al. Effects of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropethy in the streptozotocin diabetic rat[J]. Diabetologia, 2004,47(8):1385.

二级参考文献19

  • 1[1]Vlassara H,Bucala R,Striker L.Pathogenic effects of advanced glycosylatio n:Biochemical,biologic,and clinical implication for diabetes and aging[J].L ab Invest,1994,70(2)∶138-151.
  • 2[2]Vlassara H,Bucala R.Recent progress in advanced glycation and diabe tic vascular disease:role of advanced glycation end product receptors[J].Di abetes,1996,45 (Suppl 3)∶S65-S66.
  • 3[3]Makita Z,Vlassara H,Rayfield E,et al.Hemoglobin AGE:a circulati ng marker of advanced glycosylation[J].Science,1992,258(5082)∶651-653.
  • 4[4]Edelstein D,Brownlee M. Mechanistic studies of advanced glyco sylation end product inhibition by aminoguanidine[J].Diabetes,1992,41(1) ∶26-29.
  • 5[5]Hirsch J, Petrakova E, Feather MS. The reaction of some dic arbonyl sugars with aminoguanidine[J].Carbohydr Res,1992,232(2)∶125-130.
  • 6[6]Tanaka Y,Uchino H,Shimizu T,et al.Effect of metformin o n advanced glycation endproduct formation and peripheral nerve function in strep tozotocin-induced diabetic rats[J].Eur J Pharmacol,1999,376(1)∶17-22.
  • 7[7]Kochakian M,Manjula BN,Egan JJ.Chronic dosing with aminoguanidine a nd novel advanced glycosylation end product-formation inhibitors ameliorates cr oss-linking of tail tendon collagen in STZ-induced diabetic rats[J].Diabe tes,1996,45(12)∶1694-1700.
  • 8[8]Nakamura S,Makita Z,Ishikawa S,et al.Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195,a novel inhibitor of adv anced glycation[J].Diabetes,1997,46(5)∶895-899.
  • 9[9]Miyata T,Ishikawa S,Asahi K,et al.2-isopropylidenehydrazo- no-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits t he dev elopment of intimal thickening after baloon injury of rat carotid artery: role o f glycoxidation and lipoxidation reactions in vascular tissue damage[J].FEB S Lett,1999,445(1)∶202-206.
  • 10[10]Tsuchida K,Makita Z,Yamagishi S,et al.Suppression of transforming gr owth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195[J].D iabetologia,1999,42(5)∶579-588.

共引文献17

同被引文献19

  • 1施红,金国琴,余文珍.诱导构建最佳类似人类2型糖尿病大鼠的造模方式[J].中国临床康复,2005,9(39):69-71. 被引量:47
  • 2杨秀颖,杜冠华.糖基化末端终产物及相关药物研究进展[J].中国药理学报,201I,27(9):1185-1188.
  • 3Yamagishi S,Nakamura K,Matsui T.Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.Curr Drug Discov Technol,2006,3:83-88.
  • 4Stitt AW.AGEs and Diabetic Retinopathy.Invest Ophthalmol Vis Sci.2010,51:4867-4874.
  • 5诸葛启钏主译.大鼠脑立体定位图谱(第三版).北京:人民卫生出版社,2005:图37-50.
  • 6Lopes de Faria JM,Katsumi O,Cagliero E,et al.Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus.Graefes Arch Clin Exp Ophthalmol,2001,239:643-648.
  • 7Ozsoy E,Doganay S,Dogan M,et al.Evaluation of metabolite changes in visual cortex in diabetic retinopathy by MR-Spectroscopy.J Diabetes Complications,2012,26:241-245.
  • 8Kaji Y,Usui T,Isbida S,et al.Inhibition of Diabetic Leukostasis and Blood-Retinal Barrier Breakdown with a Soluble Form of a Receptor for Advanced Glycation End Products.Invest Ophthalmol Vis Sci.2007,48:858-865.
  • 9饶亚平,蒋克春,彭琦,邹涓,庞春梅,王爱萍.视觉诱发电位在糖尿病视网膜病变诊断中的应用[J].国际眼科杂志,2008,8(1):180-182. 被引量:17
  • 10邢影,常颖,王捷,韩雪梅,徐忠信.糖尿病大鼠局灶脑缺血AGEs及其受体的表达[J].中国老年学杂志,2009,29(5):565-566. 被引量:2

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部